Activity Details

0.75 AMA PRA Category 1 Credit(s)™ /
Released: September 30, 2020
Expires: September 29, 2021
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, internists, rheumatologists, and other health care professionals involved in the management of patients with progressive fibrosing interstitial lung disease (PF-ILD).

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Apply the latest guidelines to identify patients with progressive fibrosing interstitial lung disease (PF-ILD) in a timely manner.
  • Implement treatment strategies for patients with PF-ILD based on the latest clinical evidence.
  • Review the importance of treatment adherence for patients with PF-ILD and strategies to keep patients on treatment for as long as possible.
  • Evaluate effective multidisciplinary strategies to improve the comprehensive management of patients with PF-ILD.

Activity Description

Interstitial lung disease (ILD) describes a group of more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options—pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss the latest approaches to managing patients with PF-ILD.


Updates in Imaging and Diagnosis for ILD
Steven D. Nathan, MD

Updates in the Treatment of PF-ILD
Kevin R. Flaherty, MD, MS

Case Discussions
Nina M. Patel, MD

Activity Chair

Steven D. Nathan, MD
Medical Director,
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA

Consulting Fee: Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech


Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Consulting Fee: Bellerophon, Blade Therapeutics, Boehringer Ingelheim, Respivant Sciences, Shionogi, United Therapeutics
Contracted Research: Boehringer Ingelheim

Nina M. Patel, MD
Adjunct Associate Professor of Medicine
Columbia University
New York, NY

Advisory Board: Boehringer Ingelheim

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all continuing medical education (CME) providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, September 30, 2020 to September 29, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.